Passage Bio CEO departs after March layoffs as biotech goes with legal chops for interim replacement
Passage Bio’s ambitions will be handled by a new face going forward as Bruce Goldsmith exited Tuesday, adding to the list of biotechs facing the unrelenting bear market that has forced leadership shuffles to happen at breakneck speed.
The biotech said the May 31 separation was a “mutual agreement between the Board and Dr. Goldsmith,” according to an SEC filing.
Goldsmith is leaving his CEO, president and board posts at the Jim Wilson gene therapy maker just months after the biotech laid off 13% of its workforce. Also in March, R&D chief Eliseo Salinas quit as did board member Liam Ratcliffe, who disagreed with the biotech’s “business plans and operations.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.